Home World News EMA Adopts a Positive Opinion for Biosimilar Denosumab World News EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 850 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Transforming Cancer Clinical Trials for Better, Faster Results April 14, 2023 What People With Cancer Should Know About Immune Checkpoint Inhibitor Side... November 1, 2021 New Super-Microsurgical Procedure May Prevent Lymphedema in Breast Cancer Patients March 2, 2020 Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume... October 20, 2026 Load more HOT NEWS The 10-year cancer plan: is improving cancer survival still a priority... The Cancer Moonshot: Moving from Planning to Research NF1 Associated with More Cancer Types Than Previously Known Nivolumab and Ipilimumab Effective against Melanoma That Has Spread to the...
